Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
$6.48
$6.48
$2.11
$8.74
$28.12M0.6612,055 shsN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$7.08
-14.3%
$8.15
$0.85
$93.60
$46.28M2.42914,650 shs376,612 shs
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
$0.00
$0.00
$0.00
$0.07
$4K-0.0612,338 shs1,222 shs
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
$3.10
$3.10
$2.50
$13.00
$10.58M2.352,472 shsN/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
0.00%0.00%0.00%0.00%0.00%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-14.29%-8.05%-55.25%+505.13%-92.92%
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
0.00%0.00%0.00%-95.00%0.00%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.3788 of 5 stars
1.00.00.00.02.20.80.6
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
0.00
N/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
2.00
Hold$2.00-71.75% Downside
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
0.00
N/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/AN/AN/AN/A$12.07 per shareN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$60K660.80N/AN/A($695.52) per share-0.01
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
$1.10M0.00N/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/A$7.98 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
-$88.97M-$5.59N/AN/AN/AN/A-150.46%-97.01%N/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
N/A-$2.24N/AN/AN/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
-$240KN/A0.00N/AN/AN/AN/AN/A

Latest FRLN, HYPD, PHXM, and KLDO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/19/2025Q1 2025
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/AN/AN/AN/AN/A
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
N/AN/AN/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
N/A
1.95
N/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A
0.34
0.34
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
N/AN/AN/A
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.23
1.78
N/A

Institutional Ownership

CompanyInstitutional Ownership
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
46.26%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
25.84%
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
81.56%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
0.40%

Insider Ownership

CompanyInsider Ownership
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
1.90%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
10.86%
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
9.00%
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
1.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
Freeline Therapeutics Holdings plc stock logo
FRLN
Freeline Therapeutics
1524.34 million4.26 millionNot Optionable
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
405.60 million5.00 millionOptionable
Kaleido Biosciences, Inc. stock logo
KLDO
Kaleido Biosciences
8042.62 million38.79 millionNot Optionable
PHAXIAM Therapeutics S.A. stock logo
PHXM
PHAXIAM Therapeutics
493.41 million3.35 millionNo Data

Recent News About These Companies

Phaxiam Therapeutics S.A.
PHAXIAM Reports Third-Quarter 2024 Financial Information

New MarketBeat Followers Over Time

Media Sentiment Over Time

Freeline Therapeutics stock logo

Freeline Therapeutics NASDAQ:FRLN

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Hyperion DeFi stock logo

Hyperion DeFi NASDAQ:HYPD

$7.08 -1.18 (-14.29%)
As of 08/1/2025 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Kaleido Biosciences stock logo

Kaleido Biosciences NASDAQ:KLDO

$0.0001 0.00 (0.00%)
As of 08/1/2025 09:34 AM Eastern

Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

PHAXIAM Therapeutics stock logo

PHAXIAM Therapeutics NASDAQ:PHXM

$3.10 0.00 (0.00%)
As of 07/31/2025

PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.